Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 15/20 | 0.43 |
| ▸ | TP53 | P04637 | 5/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MDM4 | O15151 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CTSA | P10619 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9894216 | 0.94 | MDM2 (0.50) | MDM2TP53USP2HPGDMDM4 | |
| SCHEMBL9894475 | 0.91 | MDM2 (0.41) | MDM2TP53USP2HPGDALDH1A1 | |
| SCHEMBL9893819 | 0.88 | MDM2 (0.50) | MDM2TP53USP2HPGDALDH1A1 | |
| SCHEMBL1437222 | 0.86 | TP53 (0.38) | MDM2TP53USP2HPGDMDM4 | |
| SCHEMBL9893788 | 0.83 | MDM2 (0.53) | MDM2TP53USP2HPGDALDH1A1 | |
| SCHEMBL9893923 | 0.83 | MDM2 (0.63) | MDM2TP53HPGDALDH1A1TSHR | |
| SCHEMBL9893649 | 0.81 | MDM2 (0.52) | MDM2TP53ALDH1A1TSHRMDM4 | |
| SCHEMBL9893792 | 0.81 | MDM2 (0.48) | MDM2TP53USP2HPGDMDM4 | |
| SCHEMBL1437087 | 0.79 | MDM2 (0.48) | MDM2TP53ALDH1A1MDM4MAPT | |
| SCHEMBL9893712 | 0.79 | MDM2 (0.55) | MDM2TP53HPGDMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885TP53 3/4885USP2 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.